Aterovax's sPLA2 Activity Test Significantly Improves Prediction of Cardiovascular Events in Large Prospective Study

PARIS--(BUSINESS WIRE)--Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein. sPLA2 is in a family of pro-inflammatory enzymes linked to the formation and destabilization of atherosclerotic plaques. Aterovax’s sPLA2 activity test was used in 3778 patients in the PEACE (Prevention of Events with Angiotensin Converting Enzyme Inhibition) trial and the results were presented at the American Heart Association’s annual scientific sessions.